I/O in Lung Cancer - 4: Bristol-Myers Looks to Regain Ground for Opdivo with Immunotherapy Combos

Kiyoshi Hashigami, Head of Medical & Development Japan, Korea, and Taiwan, Senior Managing Executive Officer, Bristol-Myers Squibb K.K. By Takashi Ebisawa Ono Pharmaceutical/Bristol-Myers Squibb’s Opdivo (nivolumab) has been the leader in the checkpoint inhibitor market since it earned the world’s...read more